Navigation Links
DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix
Date:11/5/2009

PARSIPPANY, N.J., Nov. 5 /PRNewswire/ -- DSM Pharmaceutical Products today announced that it has made a manufacturing alliance with Galenix, Saint Jean D'Illac, France, where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.

DSM and Galenix will collaborate on business development opportunities co-marketing Galenix drug delivery technologies, based on the strength of Galenix in drug product development and clinical services and DSM in process development, scale up and commercial scale pharmaceutical manufacturing.

Pieter de Geus, Senior Vice President, R&D stated, "These innovative drug delivery technologies enhance our offering in the field of pharmaceutical development services and complement our portfolio of drug delivery technologies. The collaboration with Galenix clearly demonstrates DSM's commitment to bringing improved drug delivery to markets globally."

Hans Engels, President of DSM Pharmaceuticals, Inc. commented, "The alliance brings out the best of both parties. Combining innovative formulations with flawless transition into commercial products creates an attractive value proposition for any drug company."

Jerome Besse, CEO of Galenix concurred with the DSM comments, and further added, "This is truly a win-win situation. Galenix is privileged in working with DSM to generate value for our customers. The partnership fits with our strategic intention of expanding service offerings to the North America market, and also with DSM's expansion of sales & marketing focus in Europe."

No financial terms were disclosed.

Galenix

Founded in 1993 by CEO Jerome Besse, Galenix is ranked in the top European leaders for pharmaceutical R&D and drug delivery systems. Galenix provides comprehensive pharmaceutical development services to healthcare companies, from the sourcing of Active Pharmaceutical Ingredients (API's) to clinical supply services and regulatory submission. Its two major competitive strengths, in addition to a full service delivery, are the compliance of the cGMP facilities with European and American standards, as well as its extensive know-how and experience in patented, innovative drug delivery system design and drug product development. The Galenix drug delivery systems, providing improvement and better patient compliance of medicines, include Minextab® and Minextab® floating high-dosage tablet technologies; Microgix® bioavailability / solubility technology; Mucolys® film trans-mucosal absorption and Mucolys® flash sub-lingual absorption technologies; and the ODTx orodispersible /dispersible oral dosage technology with no need of water to ingest. More information: www.galenix.fr

DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

    For more information:

    DSM Pharmaceutical Products
    Guy Tiene
    Director Marketing and Communications
    Tel: 973-257-8160
    Email: guy.tiene@dsm.com

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.

SOURCE DSM Pharmaceutical Products


'/>"/>
SOURCE DSM Pharmaceutical Products
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
5. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
7. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
8. Transdel Pharmaceuticals to Present at Two Investor Conferences
9. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
10. Amylin Pharmaceuticals to Webcast Third Quarter Results
11. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a ... launch of its new line of Heavy-Duty Orbital Shakers today. , Eight New ... digital) for laboratory applications. These shakers are ideal for load capacities from ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch ... recently participated in the BiG (Biomedical Innovation Group) annual meeting in China. , ... CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... its long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party ... areas – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS ... announced the launch of its new line of Extreme Environment Shakers today. , ... require CO2 and humidity for optimal cell growth such as cell cultures, solubility ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):